Abstract
The global spread of antibacterial resistance has important implications for the current and future management of bacterial respiratory tract infections in children. Data suggest that emerging resistance to commonly prescribed antibacterials, such as macrolides and trimethoprim-sulfamethoxazole, is beginning to impact the treatment of these infections, which include acute otitis media, tonsillitis/pharyngitis and community-acquired pneumonia. There is, therefore, a need for additional agents that are active against common respiratory tract pathogens, including resistant strains and are suitable for use in children. Infection control measures to curb the clonal spread of antibacterial resistance are also extremely important.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Child
-
Child, Preschool
-
Community-Acquired Infections / drug therapy*
-
Community-Acquired Infections / epidemiology
-
Community-Acquired Infections / microbiology
-
Drug Resistance, Multiple, Bacterial*
-
Female
-
Gram-Negative Bacteria / drug effects
-
Gram-Negative Bacteria / isolation & purification
-
Gram-Positive Bacteria / drug effects
-
Gram-Positive Bacteria / isolation & purification
-
Humans
-
Infant
-
Male
-
Microbial Sensitivity Tests
-
Otitis Media / drug therapy
-
Otitis Media / epidemiology
-
Otitis Media / microbiology
-
Pharyngitis / drug therapy
-
Pharyngitis / epidemiology
-
Pharyngitis / microbiology
-
Prognosis
-
Respiratory Tract Infections / drug therapy*
-
Respiratory Tract Infections / epidemiology
-
Respiratory Tract Infections / microbiology
-
Risk Assessment
-
Severity of Illness Index
-
Tonsillitis / drug therapy
-
Tonsillitis / epidemiology
-
Tonsillitis / microbiology
-
United States / epidemiology